NCT02576457

Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis

A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects With Severe Sepsis

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether BMS-936559 is safe and has the desired pharmacologic activity in patients who have severe sepsis.

Conditions

• Severe Sepsis
• Septic Shock

Interventions

Type	Name	Description
BIOLOGICAL	BMS-936559
OTHER	Placebo

Timeline

• Start date: 2015-12-02
• Primary completion: 2017-03-15
• Completion: 2017-03-15
• First posted: 2015-10-15
• Last updated: 2017-09-15

Locations

13 sites across 1 country: United States

Regulatory

• FDA-regulated drug study